Zebra Capital Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Zebra Capital Management’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	$218K	Sell	11,599 -3,019	-21%	-$57.5K	1.09%	43
2022 Q4	$233K	Buy	14,618 +1,114	+8%	+$17.4K	0.82%	47
2022 Q3	$221K	Buy	+13,504	New	+$219K	0.84%	48
2022 Q2	–	Sell	-10,061	Closed	-$244K	–	99
2022 Q1	$244K	Sell	10,061 -9,973	-50%	-$241K	0.56%	75
2021 Q4	$468K	Sell	20,034 -7,385	-27%	-$149K	0.75%	44
2021 Q3	$455K	Buy	+27,419	New	+$529K	0.55%	54

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Zebra Capital Management's ACAD Position: Q1 2023 in Review

Zebra Capital Management reduced its Acadia Pharmaceuticals (ACAD) stake by 21% in Q1 2023, selling an estimated $57.5K and leaving 11,599 shares worth $218K. The position accounts for 1.09% of the portfolio, ranked #43.

Zebra Capital Management first reported a position in ACAD in Q3 2021 and has held it in 6 quarters since. The position peaked at $468K in Q4 2021. 232 funds tracked by Wall St. Rank hold ACAD as of Q1 2023.

Zebra Capital Management held 11,599 shares of Acadia Pharmaceuticals worth $218K as of Q1 2023.
Zebra Capital Management sold 3,019 Acadia Pharmaceuticals shares in Q1 2023, an estimated $57.5K.
Acadia Pharmaceuticals made up 1.09% of Zebra Capital Management's portfolio in Q1 2023, its #43 holding.
Zebra Capital Management first reported a position in Acadia Pharmaceuticals in Q3 2021 and has held it in 6 quarters since.
Zebra Capital Management's Acadia Pharmaceuticals position peaked at $468K in Q4 2021.
232 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2023.

Based on Zebra Capital Management's 13F filing for Q1 2023, filed 15 May 2023.